Taking certain types of drugs could increase the risk of developing dementia later in life, a study has found. Regular use of ...

Dr. Cudkowicz is the Chair of Neurology at MGH, Director of the Sean M. Healey & AMG Center for ALS, and is the Julieanne Dorn Professor of Neurology at Harvard Medical School. A member of the ...

AbbVie Inc. announced positive data from a third late-stage trial of a treatment for Parkinson's disease on Monday and said it's on track to seek approval for the drug from the Food and Drug ...

AbbVie's experimental drug to treat early Parkinson's disease met the main goal in a late-stage study, the drugmaker said on ...

Seoul National University Bundang Hospital ('SNUBH'), CurePSP, Inc. ('CurePSP') and GemVax & KAEL Co., Ltd. ('GemVax'; KOSDAQ: 082270) have announced the establishment of Korea's first International P ...

Tavapadon hit the primary endpoint in one phase 3 trial in April, before AbbVie closed the takeover, and racked up another victory in September. AbbVie completed the set Monday by reporting data from ...

"The best medication for Parkinson's will come from Israel. It will be a hybrid medication, and the world's best hybrid ...

The darlings of the weight loss and diabetes spaces, GLP-1 receptor agonists have shown promise against Alzheimer’s in recent studies—with Phase III results expected next year from Novo Nordisk.

Intra-Cellular Therapies is developing Lenrispodun for the treatment of patients with Parkinson's Disease in a phase 2 study.

Stephen Knight, whose nonprofit saves lives by providing foster care for dogs while their owners focus on addiction recovery, ...

A study from the University of Arizona shows that the protein PNA5 helps protect brain cells, offering a promising avenue for ...

The funding comes from a county program that offers cash to businesses that want to expand locally and add at least 10 new ...